A new analysis challenges a long-held assumption in diabetes prevention: rather than focusing solely on losing weight, keeping blood glucose within normal limits may be more important for lowering the risk of progressing from prediabetes to type 2 diabetes.
Researchers from the University Hospital of Tübingen, Helmholtz Munich, and the German Center for Diabetes Research analyzed data from more than 1,100 participants in a long-term lifestyle intervention. They found that even among individuals who did not lose weight—or who gained weight—those who successfully returned their blood sugar levels to the normal range (i.e. remission of prediabetes) had a 71 % lower risk of developing type 2 diabetes over the follow-up period. That figure closely matches the 73 % risk reduction seen in participants who lost weight and normalized glucose levels.
Prediabetes affects tens of millions of people globally. In this condition, blood glucose is elevated but not yet high enough to qualify as diabetes. Because early stages often show no symptoms, many cases go undiagnosed. Left unchecked, prediabetes can lead to type 2 diabetes, which is associated with serious complications including cardiovascular disease, kidney damage, and increased cancer risk.
Rethinking prevention: fat distribution, not just pounds
Conventional guidelines and prevention programmes have prioritized weight reduction—through dietary restriction and increased physical activity—as the principal route to diabetes prevention. But this latest evidence suggests a need to broaden the target: restoring normal glucose control may itself be therapeutic, even without weight loss.
The underlying mechanism may lie in fat distribution, not total mass. Visceral fat (around internal organs) is metabolically dangerous: it promotes inflammation, hormonal imbalance, and insulin resistance. Subcutaneous fat (just under the skin), by contrast, has less harmful metabolic impact. In the Tübingen cohort, those who normalized glucose without losing weight tended to reduce visceral fat more than those whose glucose remained high.
As Prof. Andreas Birkenfeld, a lead author, put it:
“Restoring a normal fasting blood sugar level is the most important goal in preventing type 2 diabetes and not necessarily the number on the scale.”
He emphasizes that while weight loss remains beneficial, it may not be strictly necessary for diabetes protection if glycemic control improves.
Coauthor Prof. Reiner Jumpertz-von Schwartzenberg adds that future clinical guidelines should shift away from a purely weight-centric view toward one that also explicitly incorporates blood sugar targets.
What this means for prevention and treatment
This paradigm shift has practical implications:
Target glycemic control alongside weight: In clinical practice, setting goals for fasting glucose or HbA1c (rather than just weight loss) may lead to better prevention outcomes.
Lifestyle still foundational: Diet quality, physical activity, and behavioral support remain essential to help individuals move into remission of prediabetes—even if weight loss is modest.
Personalization matters: Some individuals may achieve remission with modest changes; others may require more aggressive interventions, including weight loss or medication.
Supporting early intervention: Because remission is more plausible earlier in the disease trajectory, early detection and monitoring of glucose are critical.
Other recent research reinforces the importance of lifestyle habits. A study showed exercising more than 150 minutes per week significantly increased the odds of reverting from prediabetes to normal blood sugar levels. Even in controlled interventions, modest improvements in diet, weight, and exercise had measurable benefits.
Meanwhile, long-term studies like the Diabetes Prevention Program (DPP) confirm that weight-loss–based interventions continue to offer enduring protection. Over decades, such programmes reduced the incidence of type 2 diabetes, though many participants regained weight—suggesting that sustained behavior change and metabolic improvements matter.
In the UK, the NHS has launched a “Type 2 Diabetes Path to Remission” programme. It uses a structured low-calorie diet (via nutrition replacement products for several months) and behavioral support to induce remission in eligible patients. Early results show that around 32 % of participants achieved remission after one year.
At the same time, issues around weight loss clinics are gaining public attention. In England, the rollout of Wegovy (a high-efficacy weight-loss drug) has been limited in part due to a shortage of specialist weight management clinics capable of prescribing it. Only a fraction of anticipated prescriptions have been made, raising concerns about inequality in access.
There is also political momentum to expand the availability of weight-loss drugs more broadly. Plans are being considered to offer injections like Mounjaro and Wegovy through community pharmacies, bridging gaps in traditional healthcare pathways.
YOU MAY ALSO LIKE
Diabetic Diet: 7 Fruits to Limit or Avoid for Better Blood Sugar Control
Rising Blood Sugar Linked to Sexual Health Decline in Aging Men
Ginger Found to Reduce Blood Sugar and Inflammation Effectively
